SCHEMBL22200583

SCHEMBL22200583

Cc1ccc(CSNc2ccc(-c3nc4cnc(N)nc4n(C(C)C)c3=O)cc2F)c(C#N)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ERN1 O75460 3/20 0.54
MTOR P42345 7/20 0.34
PIK3CD O00329 3/20 0.33
PIK3CA P42336 3/20 0.32
ABL1 P00519 2/20 0.32
EGFR P00533 2/20 0.32
HCK P08631 2/20 0.32
SRC P12931 2/20 0.32
KDR P35968 2/20 0.32
PIK3CB P42338 2/20 0.32
PIK3CG P48736 2/20 0.32
EPHB4 P54760 2/20 0.32
PRKDC P78527 2/20 0.32
CYP1A2 P05177 4/20 0.31
HSD17B10 Q99714 4/20 0.31
ALDH1A1 P00352 3/20 0.31
CYP3A4 P08684 3/20 0.31
USP2 O75604 2/20 0.31
MEN1 O00255 2/20 0.31
CYP2D6 P10635 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22200361 0.91 ERN1 (0.45) ERN1MTORPIK3CDPIK3CAABL1
SCHEMBL22200589 0.90 ERN1 (0.46) ERN1MTORPIK3CACYP1A2HSD17B10
SCHEMBL25035489 0.86 ERN1 (0.70) ERN1MTORPIK3CDPIK3CAABL1
SCHEMBL22200345 0.85 ERN1 (0.53) ERN1MTORCYP1A2HSD17B10ALDH1A1
SCHEMBL22200603 0.82 ERN1 (0.43) ERN1MTORCYP1A2HSD17B10ALDH1A1
SCHEMBL22200338 0.82 ERN1 (0.41) ERN1MTORCYP1A2HSD17B10ALDH1A1
SCHEMBL22200356 0.81 ERN1 (0.41) ERN1MTORPIK3CACYP1A2HSD17B10
SCHEMBL22200601 0.81 ERN1 (0.43) ERN1MTORPIK3CDPIK3CAABL1
SCHEMBL22200731 0.81 ERN1 (0.46) ERN1CYP1A2HSD17B10ALDH1A1CYP3A4
SCHEMBL22200353 0.80 ERN1 (0.40) ERN1MTORPIK3CDPIK3CACYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2020142612-A1 PYRIDO-PYRIMIDINONE AND PTERIDINONE COMPOUNDS AS INHIBITORS OF ENDORIBONUCLEASE INOSITOL REQUIRING ENZYME I (IRE I ALPHA) FOR THE TREATMENT OF CANCER DISEASES. GENENTECH, INC. (US) 2020-07-09 WO disclosed